VJHemOnc is committed to improving our service to you

EHA 2019 | ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL

VJHemOnc is committed to improving our service to you

Paolo Ghia

Paolo Ghia, Università Vita-Salute San Raffaele, Milan, Italy, discusses the late-breaking abstract data on the ASCEND trial (NCT02970318) of acalabrutinib in previously treated chronic lymphocytic leukemia (CLL). This treatment was demonstrated to significantly prolong survival without disease progression, indicating that acalabrutinib has the potential to change current practice by providing a well-tolerated, highly effective BTK inhibitor treatment. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter